FindTrial
Sign In

Risk factors of osteonecrosis of the jaw in patients with multiple myeloma receiving IV bisphosphonates

Risk factors of osteonecrosis of the jaw in patients with multiple myeloma receiving intravenous bisphosphonates: Retrospective study

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20230206007
Enrollment
120
Registered
2023-02-06
Start date
2023-02-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients diagnosed with multiple myeloma and had received intravenous bisphosphonates. Risk factor, Multiple myeloma, Intravenous bisphosphonate

Interventions

Patients diagnosed with multiple myeloma received intravenous bisphosphonates.
Screening
IV Bisphosphonate in patient with multiple myeloma

Sponsors

Chulalongkorn University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with multiple myeloma received intravenous bisphosphonates. 2. Patients who evaluate and/or treated as a new case or relapse of multiple myeloma.

Exclusion criteria

Exclusion criteria: 1. Patients had a history of radiation therapy to the jaws or of tumors or cysts. 2. Undergoing a radiation therapy in the head and neck region 3. Patients had a history of osteonecrosis of the jaw before treating multiple myeloma with IV bisphosphonate.

Design outcomes

Primary

MeasureTime frame
Osteonecrosis of the jaw Time between beginning of IV bisphosphonate to the date diagnosed osteonecrosis of the jaw ICD 10—

Secondary

MeasureTime frame
N/A N/A N/A—

Countries

Thailand

Contacts

Public Contactsirachat nuengjumnong

Faculty of Dentistry, Chulalongkorn University

sirachatjack@gmail.com0896020709

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026